SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shasun Pharma acquires global rights of Ibuprofen 12 hour extended release OTC

05 May 2014 Evaluate

Shasun Pharmaceuticals, Chennai, India an integrated pharmaceutical company through its wholly owned subsidiary, SVADS Holdings, Switzerland (SVADS) has acquired the global rights from ScolrPharma, USA (Scolr), to develop and commercialize Ibuprofen 12 hour Extended Release OTC tablets (Asset) as well as the associated Controlled Release Technology (CDT) along with global rights of Nuprin trademark, a well known brand in Analgesics. The Asset, having completed a successful Phase III in the US is a differentiated long acting NSAIDS in the Multi Billion Dollar global OTC analgesic market.

Shasun is the world's leading, vertically integrated manufacturer of Ibuprofen and its Derivatives, from actives to formulated packaged products for both the Rx and OTC markets. This acquisition complements Shasun's strategy to expand its range of NSAIDS products through novel, safe and efficacious delivery technologies including transdermal applications across its Ibuprofen franchise.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1667.70
Dr. Reddys Lab 1230.20
Cipla 1227.90
Zydus Lifesciences 933.90
Lupin 2327.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×